Graefe's Archive for Clinical and Experimental Ophthalmology

, Volume 252, Issue 9, pp 1477–1481

Five-year outcome in immune-mediated scleritis

Authors

    • OMMA Eye Center
    • Department of OphthalmologyUniversity Hospital of Zürich
  • Beat Pleisch
    • OMMA Eye Center
  • Matthias Brunner
    • OMMA Eye Center
Inflammatory Disorders

DOI: 10.1007/s00417-014-2696-1

Cite this article as:
Bernauer, W., Pleisch, B. & Brunner, M. Graefes Arch Clin Exp Ophthalmol (2014) 252: 1477. doi:10.1007/s00417-014-2696-1
  • 229 Views

Abstract

Background

Immune-mediated scleritis is a rare condition, and the information on the clinical course and complications is scarce. The aim of this study was to identify prognostic factors, complications, and therapeutic effects in patients with immune-mediated scleritis.

Methods

Patients with diagnosis of scleritis and a follow-up time of 5 years were identified. Systemic disease, laboratory investigations, type of scleritis, disease activity, therapy, and complications were recorded. The study design was a retrospective, non-comparative, interventional case series.

Results

Systemic disease was identified in 15 (37 %) patients at presentation and in 18 (45 %) after 5 years. Rheumatoid arthritis (15 %), granulomatosis with polyangiitis (7.5 %), and polychondritis (7.5 %) were the most predominant disorders. Persistent scleritis (>5 years) was associated with systemic disease (66 vs. 6 %; p < 0.05) and positive auto-antibodies (48 vs. 23 %; p = 0.18). Control of ocular inflammation was achieved in 38 of 40 (95 %). Prednisone (14 patients) and/or methotrexate (8) were the predominant drugs to control persistent disease. Complications included interstitial keratitis (2), inflammatory astigmatism (2), corneal melt (3), macular edema (6), and severe systemic disease (5).

Conclusion

The presence of systemic disease and positive auto-antibodies are associated with persistent scleritis. Immunosuppressive agents allow control of scleritis, but may contribute to severe systemic complications.

Keywords

ScleritisCorneaKeratitisOutcomeInflammationImmunopressive therapySteroids

Copyright information

© Springer-Verlag Berlin Heidelberg 2014